Scalper1 News
Leading biotech names took hits Friday, but it’s too early to say if the group is ready to surrender its market leadership. One day after assuming the top slot in IBD’s 197 Industry Group Rankings screen (today on B15), the biotech group got hit hard Friday, falling about 2%. But year-to-date, the group is still up 25%, easily topping a 10% gain for the S&P 500. Celgene (CELG) had been holding gains nicely after reclaiming a 90.60 flat-base buy Scalper1 News
Scalper1 News